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1. Introduction  
Human T cell leukemia virus 1 (HTLV-1), the first characterized human retrovirus, has been 
identified as the causative agent for adult T-cell leukemia/lymphoma (ATLL). This 
aggressive lymphoid proliferation is associated with a bad prognosis due to the resistance of 
HTLV-1-infected cells to most classical chemotherapeutic agents.  
HTLV-1 is transmitted intravenously, by sexual contact, or through breast-feeding from 
mother to child, and epidemiological evidence predicts that ATLL development occurs 
following childhood infection. ATLL exhibits diverse clinical features: the acute, the sub-
acute or smoldering, the chronic forms and the ATL lymphoma. In the two most aggressive 
forms (acute leukemia and lymphoma), the tumor syndrome comprises massive 
lymphadenopathy, hepatosplenomegaly, lytic bone lesions and multiple visceral lesions 
with skin and lung infiltration. 
HTLV-1 virions infect CD4+ T cells, which represent the main target for HTLV-1 infection in 
peripheral blood. HTLV-1 associated diseases occur after long periods of virus latency. For 
years it has been thought that unlike other retroviruses, free virions were poorly infectious. 
However, a recent study reported that freshly isolated myeloid dendritic cells (mDC) and 
plasmacytoid dendritic cells (pDC) are efficiently and productively infected by cell-free 
HTLV-1. Furthermore, infected mDC and pDC were able to transfer virions to autologous 
CD4+ T cells, clearly demonstrating that cell free HTLV-1 can be infectious and target 
dendritic cells. Innate immune response against HTLV-1 is poorly documented. 
We describe here immune response against HTLV-1 and physiological consequences. 
2. The Human T cell leukemia virus 1 (HTLV-1) 
In 1980 the group of Robert C. Gallo characterized the first human retrovirus, the Human T 
cell leukemia virus 1 (HTLV-1) (Poiesz, Ruscetti et al., 1980). This virus was recovered from 
the peripheral blood cells of a patient suffering from adult T-cell-leukemia/lymphoma 
(ATLL). This form of leukemia is a severe T-cell lymphoma proliferation with bad 
prognostic due to the resistance of HTLV-1-infected cells to most classical chemotherapeutic 
agents.  
We first describe here the epidemiology, the genomic of HTLV-1 virus and its receptor 
complex. 
2.1 HTLV-1 genomic characteristics 
HTLV-1 is classified as a complex retrovirus, in the genus delta-retrovirus of the 
subfamily Orthoretrovirinae. HTLV-1 retrovirus genetic material is composed by a 
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diploid single strain RNA (Figure 1). The length of the HTLV-1 genome is 9.032 basepair 
(bp). The group antigens are similar to other retroviruses-(gag), polymerase (pol), and 
envelope (env) genes are flanked by long terminal repeats (LTR). The LTR consists of U3, 
R and U5 regions. The U3 region of HTLV-1 controls the virus transcription. It contains 
essential elements such as the TATA box, which is necessary for viral transcription, a 
sequence that causes termination and polyadenylation of the RNA messenger and Tax 
responsive elements (TRE) involved in Tax protein transcription which regulates the 
transcription of the HTLV-1 provirus. The R region overlaps the 3´ of the U3 region and 
contains the majority of the Rex response element. The “gag” gene encodes the virus core 
protein, which is initially synthesized with approximatively molecular weight of 53 kD. 
During viral maturation this precursor is cleaved to form the matured matrix P19 (MA), 
the capsid P24 (CA) and the nucleocapsid P15 (NC).  
HTLV-1 virions are enveloped into a lipidic membrane and a nucleocapsid that protect the 
genetic material, the ribonucleic acid (RNA). The lipidic membrane is derived from cellular 
plasma membrane. The envelope proteins are constituted by the glycoprotein (gp) 21 
(Transmembrane subunit, TM) and gp46 (Surface subunit, SU), which are coded by env and 
are integrated to the lipidic membrane. Matrix protein p19 and p24 are coded by gag and 
constitute the intern core of viral envelope. The nucleocapsid p15 is also coded by gag and is 
enveloping the genetic material composed of a diploid single stranded RNA (Figure 1). 
 
 
Fig. 1. Genomic and proteic structure of HTLV-1 virion. 
2.2 HTLV-1 epidemiology 
Over the course of more than 30 years, the epidemiology of HTLV-1 has matured. 
Epidemiologic studies are based on serologic diagnosis by detection of specific antibodies 
using enzyme-linked immunosorbent assay (ELISA) or by agglutination assay. Thus, the 
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serologic is confirmed by immunoblot of specific antibodies and polymerase chain reaction 
(PCR) of genomic DNA from cells of infected patients.  
The number of HTLV-1 infected people is elevated and the most recent studies estimated at 
15-20 millions people infected worldwide (Verdonck, Gonzalez et al., 2007). Epidemiologic 
studies revealed that density of infected individuals were in Malaysia, Caribbean, Africa 
(Gabon, Cameroun), South America (Brazil, Guyana, Colombia) and South Japan (Figure 2). 
However, these numbers are only estimations and probably do not reflect the reality. 
Indeed, most of infected people are not diagnosed due to the complex and expensive 
methods of diagnosis. Thus, number of people really infected might be higher especially in 
developed countries. 
Among the HTLV-1-infected population, around 3 to 6% develop the ATLL syndrome. 
HTLV-1 infection is highly concentrated in some regions especially in South Japan where 
the prevalence can reach as high as 37% in a selected population (Mueller, Okayama et al., 
1996; Yamaguchi, 1994). The reasons for HTLV-1 clustering, the high ubiquity in 
southwestern Japan but low prevalence in neighboring regions of Korea, China and Eastern 
Russia are still unknown. For nonendemic geographic regions, HTLV-1 is mainly found in 
immigrants. The contamination is largely due to sexual contacts with sex workers. However, 
the prevalence in Europe and North America remains extremly low and does not exceed 




Fig. 2. Origin, spread, and prevalence of HTLV-1. 
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HTLV-1 is transmitted intravenously, by sexual contact, or through breast-feeding from 
mother to child, and epidemiological evidence predicts that ATLL development occurs 
following childhood infection. Mother to child transmission occurs very frequently (around 
20%) and is related to mother viral load and prolonged breast-feeding. Indeed, it is now well 
accepted that HTLV-1 could be transmitted through mother’s milk and is one of the major 
factor in vertical transmission. Thus, screening of HTLV-1 among blood donors had been 
extended and breast-feeding among HTLV-1-infected women had been refrained in Japan 
decreasing vertical transmission. 
Finally, it is also possible that HTLV-1 could be transmitted by saliva, which contains 
HTLV-1 antibodies and proviral DNA. However, there is no clear study demonstrating this 
way of contamination (Fujino and Nagata, 2000). 
Origin and spread hypothesis based on phylogenetic and anthropological data. HTLV-1 
originated in African primates and migrated to Asia where it evolved into STLV-1. This 
early STLV-1 lineage spread to India, Japan, Indonesia, and back to Africa (arrows 1). It 
crossed the simian–human barrier in Indonesian human beings who migrated to Malesia, 
resulting in the HTLV-1c subtype (arrows 2). In Africa, STLV-1 evolved through several 
interspecies transmissions into HTLV-1a, HTLV-1b, and HTLV-1d, HTLV-1e, and HTLV-1f 
(arrows 3). Because of the slave trade and increased mobility, HTLV-1a was introduced in 
the New World, Japan, the Middle East, and North Africa (arrows 4). Colours indicate 
current prevalence estimates based on population surveys and on studies in pregnant 
women and blood donors. In some countries, HTLV-1 infection is limited to certain 
population groups or areas. (Verdonck, Gonzalez et al., 2007). 
2.3 HTLV-1 receptor complex 
For years the HTLV-1 receptor remained unknown and a real mystery. Serious evidences 
indicated that HTLV-1 entry requires the viral envelope glycoprotein (Env), the surface 
subunit gp46 and the transmembrane subunit gp21, generated from the clivage of a 
precursor gp61. Mutation in any of this proteins or use of blocking antibodies dramatically 
reduced HTLV-1 infection. Thus, one study demonstrated that glucose transporter GLUT1 
was the receptor for HTLV-1 (Manel, Kim et al., 2003). GLUT1 matched all requirement for 
HTLV-1 entry. GLUT1 is overexpressed by activated T cells, which are targets of HTLV-1. 
Using small interfering RNA siRNA strategy they demonstrated that downregulation of 
GLUT1 in cell lines reduced HTLV-1 infection. Furthermore, GLUT1 transfection of GLUT1 
negative cells restored HTLV-1 infection, demonstrating that GLUT1 is an essential 
component of HTLV-1 receptor. More recently, it has been suggested that two other 
molecules are involved in HTLV-1 infection of target cells: neuropilin 1 (NRP-1) and 
Heparan Sulfate Proteoglycans (HSPG) (Ghez, Lepelletier et al.).  
The Neuropilin-1 was initially identified as a embryonic neurons guidance factor. NRP-1 is a 
glycoprotein receptor for Semaphorin 3a and VEGF (Vascular endothelial growth factor). It 
also has been showed that NRP-1 was a key molecule in angiogenesis and is also implicated 
in the regulation of immune response (Tordjman, Lepelletier et al., 2002). It has been showed 
that NRP-1 directly binds HTLV-1 virus. The interaction appeared functionnaly relevant 
since NRP-1 overexpression enhanced syncytium formation in vitro. Furthermore, confocal 
analysis revealed a strong polarisation of NRP-1 and viral glycoprotein Env at the interface 
of an infected cell and a target T cell (Ghez, Lepelletier et al., 2006).  
HSPG family members are composed of a core protein associated with one or several 
sulphated polysaccharide side chains (i.e. sulfate glycosaminoglycans). Sulphated 
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polysaccharide side chains confer to HSPG members electrostatic properties that allow 
binding to a very large range of proteins, including cytokines, receptors, hormones, 
chemokines and extracellular matrix proteins. HSPG enhances infection by facilitating the 
attachment of the particles on target cells and/or allowing their clustering at the cell surface 
before specific interactions between viral proteins and their receptors that lead to fusion. 
HSPG had been showed to bind the HIV-1 protein gp120, therefore facilitating HIV-1 
infection. Studies demonstrated that inhibition of HSPG dramatically reduced syncitium 
formation and infection in CD4+ T cells (Lambert, Bouttier et al., 2009). Furthermore, 
inhibition of HSPG also reduced infection of dendritic cells. Thus, a model involving three 
partners had been proposed (Figure 3). 
 
 
Fig. 3. Model for HTLV-1 receptor complex. 
From Ghez, Lepelletier et al., 2006. 
More recently, one study proposed another model for HTLV-1 entry into target cells (Pais-
Correia, Sachse et al.). This model proposes that HTLV-1-infected T lymphocytes transiently 
store viral particles as carbohydrate-rich extracellular assemblies. These carbohydrate 
assemblies are attached to cell surface and held together by virally-induced extracellular 
matrix components. This extracellular matrix is made of protein such as collagen, agrin, 
galectin-3 and tetherin. It should be noted that HSPG is probably a protein of the HTLV-1 
extracellular assemblies. This kind of structure was first discovered for bacteria and called 
“biofilm”. Authors showed that extracellular HTLV-1 biofilms adhere to other cells 
facilitating viral binding and infection. This form of viral infection is extremely efficient due 
to high concentration of extracellular viruses on cell surface.  
Thus, HTLV-1 may use several strategies to infect target cells.  However, further studies are 
needed to clarify the entry of HTLV-1 in patients. 
www.intechopen.com
 T-Cell Leukemia 
 
6 
3. The adult T-cell leukemia/lymphoma (ATLL) 
Adult T cell leukemia/lymphoma (ATLL) had been shown to be a consequence of HTLV-1 
infection (Hinuma, Gotoh et al., 1982). HTLV-1 infection is also responsible for 
myelopathy/tropical spastic paraparesis (HAM/TSP) (de The, Gazzolo et al., 1985; Gessain, 
Barin et al., 1985), uveitis and infective dermatitis in children (Manns et al., 1999). We focus 
in this section on the complex T-cell leukemia/lymphoma induced by HTLV-1 infection.  
3.1 HTLV-1 induces T cell leukemia 
In the late seventies, a group of leukemia patients with characteristic clinical features and 
particular geographical distribution were identified. Uchiyama et al proposed adult T cell 
leukemia (ATL) as a new disease. In 1980 the group of Robert C. Gallo characterized the first 
human retrovirus responsible for ATL, the Human T cell leukemia virus 1 (HTLV-1) (Poiesz, 
Ruscetti et al., 1980). 
Since then, HTLV-1 has been identified as the causative agent for two major syndromes: the 
adult T-cell leukemia (ATL) (Poiesz, Ruscetti et al., 1981; Robert-Guroff, Nakao et al., 1982) 
and the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (Jacobson, 
1996). More recently, HTLV-1 also has been shown as the causative agent for uveitis and 
infective dermatitis in children (Manns, Miley et al., 1999). Among the HTLV-1-infected 
population, around 3 to 6% develop the ATL syndrome. At the present time, it is not known 
why some infected patients develop ATL and others do not. 
3.2 ATL syndrome 
The ATL exhibits diverse clinical features and outcome is directly correlated to ATL 
subtype. The malignancy ranges from a very indolent and slowly progressive lymphoma to 
a very aggressive and nearly uniformaly lethal proliferative lymphoma. The incidence of 
ATL is estimated to be 61/100,000 HTLV-1 carriers, and the crude lifetime risk for 
developing ATL is 7.3% for males and 3.8% for females. Four types of ATL had been 
described based on the number of abnormal T cells in peripheral blood, tumor lesions in 
organs, serum lactic acid dehydrogenase (LDH) level and clinical course: the sub-acute or 
smoldering (5%), the acute (55%), the chronic forms (20%) and the ATL lymphoma (20%).  
Patients with smoldering ATL exhibit skin lesions, minimal lymph node enlargement and 
few leukemic cells in blood. Chronic ATL is characterized by mild symptoms and longer 
clinical course. In the two most aggressive forms (acute leukemia and lymphoma), the 
tumor syndrome comprises massive lymphadenopathy, hepatosplenomegaly, lytic bone 
lesions and multiple visceral lesions with skin and lung infiltration. Acute ATL is also 
characterized by general malaise, fever, cough, high lactate deshydrogenase (LDH) serum 
levels, and appearance of multilobulated nuclei leukemic cells. This aggressive lymphoid 
proliferation is associated with a bad prognosis due to the resistance of HTLV-1-infected 
cells to most classical chemotherapeutic agents. The cancer is thought to be due to the pro-
oncogenic effect of viral DNA incorporated into host lymphocytes DNA, and chronic 
stimulation of the lymphocytes at the cytokine level may play a role in development of 
malignancy. The time between infection and onset of cancer also varies geographically. It is 
believed to be about sixty years in Japan, and less than forty years in the Caribbean.  
3.3 The ATL cell 
The ATL cell is easily characterized by histological and/or cytological infiltration by flower 
cells (Matsuoka, 2005) that are malignant activated lymphocytes with convoluted nuclei and 
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basophilic cytoplasm, a multilobed nucleus with a flower shape (Figure 4). ATL cells express 
most of T cell markers (CD2, CD3, CD4, CD45RO) and more rarely CD8. However, ATL 
cells also express the alpha chain of IL-2 receptor, CD25, and T cell activation markers such 
as major histocompatibility complex HLA-DR and HLA-DQ. ATL is well known to infiltrate 
various organs and tissues, such as the skin, lungs, liver, gastrointestinal tract, central 
nervous system and bone. This infiltrative tendency of leukemic cells is possibly attributable 
to the expression of various surface molecules, such as chemokine receptors and adhesion 
molecules. Skin-homing memory T-cells uniformly express CCR4, and its ligands are 
thymus and activation-regulated chemokine (TARC) and macrophage-derived chemokine 
(MDC). CCR4 is expressed on most ATL cells. In addition, TARC and MDC are expressed in 
skin lesions in ATL patients. Thus, CCR4 expression should be implicated in the skin 
infiltration (Yoshie, 2005). On the other hand, CCR7 expression is associated with lymph 
node involvement (Kohno, Moriuchi et al., 2000). OX40 is a member of the tumor necrosis 
factor family and was reported to be expressed on ATL cells (Imura, Hori et al., 1997; 
Kunitomi, Hori et al., 2002).  
 
 
Fig. 4. Typical "flower cell" in the peripheral blood of an acute ATL patient observed on 
microscope. In the peripheral blood of an acute ATL patient, leukemic cells with 
multilobulated nuclei (Matsuoka, 2005). 
3.4 Treatment of ATL 
Adult T cell leukemia is an agressive malignant disease that results from HTLV-1 infection. 
The prognostic is directly correlated to the ATL subtype. Since ATL is a neoplasm of mature 
T cells, it has been treated with chemotherapies for non-Hodgkin's lymphoma. Conventional 
chemoterapy (LSG15) had only transcient effect and the prognostic remains poor. The 
median survival time (MST) never exceeded 10 month. 
Therefore, new therapeutic strategies were tested to adapt treatment to ATL subtype 
reviewed by Kimiharu Uozumi (Uozumi). New strategies can be divided in 3 main groups: 
chemical anti-tumor agents, monoclonal antibodies and vaccination.  
Among new chemical anti-tumor agents the combined use of anti-retroviral drug AZT and 
recombinant interferon alpha (IFN-) showed promising results (Hermine, Bouscary et al., 
1995). The MST was increased in most patients and this therapy constitutes one of the most 
efficient at the present time.  
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Similarly the combined use of arsenic trioxid and interferon alpha exhibits an anti-leukemia 
effect in very poor prognosis ATL patients despite a significant toxicity (Hermine, Dombret 
et al., 2004). 
Treatment using monoclonal antibodies and recombinant cytokines are also very promising. 
We will describe later in section 4 the use of TNF-related Apoptosis Inducing Ligand 
(TRAIL), a Tumor Necrosis Factor (TNF) superfamily member (Wiley, Schooley et al., 1995), 
as a new therapeutical strategy to induce ATL cells apoptosis. 
4. HTLV-1 and immune response 
HTLV-1 is a retrovirus and therefore is recognised by the immune system as foreign agent. 
Immune system is activated after infection and produce specific anti-HTL-1 antibodies. 
Most of immune cells respond to HTLV-1 virions. However, because symptoms occur after 
a long period of latency it is extremely hard to study acute infection. Thus, most of  
immunologic studies are performed using samples from patients infected since several 
years. We review in this section the interactions between immune cells and HTLV-1 and 
provide some new features concerning innate immune response. 
4.1 Immune cell activation by HTLV-1 
HTLV-1 like HIV-1 is a retrovirus and induces a chronic disease. Although a large number 
of studies have indicated that initial virus infection involves majority viral invasion of CD4+ 
T cells, which represent an important target for HTLV-1 infection in the peripheral blood, 
additional evidence has demonstrated that HTLV-1 can infect several additional cellular 
compartments in vivo, including CD8+ T lymphocytes, monocytes, dendritic cells, B 
lymphocytes residing in the peripheral blood and lymphoid organs or resident central 
nervous system (CNS) astrocytes (Koyanagi, Itoyama et al., 1993; Macatonia, Cruickshank et 
al., 1992; Nagai, Kubota et al., 2001; Richardson, Edwards et al., 1990).  
Transient phase of reverse transcription of viral RNA is followed by a persistent phase of 
clonal expansion within the CD4+ and CD8+ T cell populations (Mansky, 2000; Mortreux, 
Leclercq et al., 2001). Very little viral gene expression and low amounts of infectious virus 
production of HTLV-1 infected monocyte/macrophage lineage and dendritic cells are likely 
attributable to their postmitotic status and relatively short lifetime (Banchereau and 
Steinman, 1998; Valledor, Borras et al., 1998).  
This differential viral gene expression between T and dendritic cells depending of viral 
clonal expansion and expression drives the HTLV-1 immune response. Although dendritic 
cells have a low level of viral gene expression, recent evidence has suggested that HTLV-1-
infected dendritic cells exhibit an enhance capacity to stimulate antigen-specific T cell 
activation (Makino, Shimokubo et al., 1999). Furthermore, the Th1-type cytokines IL-1b, 
interferon- (IFN-), and TNF- were overexpressed in asymptomatic carriers and patients 
with HAM/TSP, while the Th2/Th3-type cytokine transformin growth factor (TGF-) was 
overexpressed in patients with ATL (Tendler, Greenberg et al., 1991). Several events may 
lead to stimulation of a Th1 or a Th2/Th3 T cell response besides the subset of dendritic cells 
(DC1 and DC2) that are first encountered antigen, or depending of the pathogen, 
recognition receptors and site of exposure (Pulendran, Palucka et al., 2001). Furthermore, the 
type of T cell response is dependent of both DC ontogeny, but also of the dendritic cell 
activating stimulus (Grabbe, Kampgen et al., 2000). Consequently, the initial route of 
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infection determines the preferential infection of dendritic cell subsets but these 
consequences of event remain unknown. 
Furthermore, the proportion of blood and secondary lymphoid organs HTLV-1+ DC is 
proportional to the total proviral DNA load in the blood, providing a correlation of 
proviral DNA load and the frequency of effector/memory Tax- CD8+ T cells (Nagai, 
Kubota et al., 2001). 
HTLV Tax oncogene may be released and act as a cytokine on neighboring cells in the CNS 
inducing NF-kB nuclear localization and immunoglobulin  light chain, IL-2Ra, IL-1b, IL-6, 
TNF-, and TNF- expression (Lindholm et al., 1990; Lindholm et al., 1992; Marriott et al., 
1992; Dhib-Jalbut et al., 1994). The cytokine like effects of Tax may induce a signaling 
cascade by binding to a specific cell surface receptor (DC1 and/or DC2 NP-1).  
Interestingly, one of the members of the interferon regulatory factor (IRF) family – IRF-4 – 
was shown to be highly expressed in cells derived from patients with ATL and in HTLV-1 
infected cell lines (Imaizumi, Kohno et al., 2001; Mamane, Grandvaux et al., 2002; Mamane, 
Loignon et al., 2005; Sharma, Grandvaux et al., 2002; Sharma, Mamane et al., 2000; Yamagata 
et al., 1996). A detailed analysis of IRF-4 has implicated the viral Tax protein in mediating 
activation of the Sp1, NF-kB and NF-AT pathways leading to a feed back loop mediated by 
Tax (Grumont and Gerondakis, 2000; Sharma, Grandvaux et al., 2002; Sharma, Mamane et 
al., 2000).  
4.2 ATL and TRAIL-induced apoptosis 
Induction of tumor cell death by apoptotic molecules is one of strategy that could be used to 
selectively reduce cancer cell proliferation without damaging normal tissue. The tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a TNF superfamily 
member, has been shown to induce apoptosis of the vast majority of tumor cell lines (Wiley, 
Schooley et al., 1995). TRAIL-induced apoptosis is finely regulated by the expression of two 
groups of receptors. Three receptors do not induce apoptosis (Decoy Receptors, DcR) and 
two activate apoptosis of target cells (Death Receptor 4 and 5, DR4, DR5) (Sheikh, Burns et 
al., 1998; Sheridan, Marsters et al., 1997; Wu, Burns et al., 1997). The two biologically active 
forms of TRAIL, membrane-bound (mTRAIL) and soluble TRAIL (sTRAIL), are regulated 
by type I interferon (interferon-alpha and beta: IFN- and IFN-)(Ehrlich, Infante-Duarte et 
al., 2003; Sato, Hida et al., 2001; Tecchio, Huber et al., 2004). TRAIL active form consist of a 
trimer stabilized by a zinc molecule. TRAIL is secreted by leukocytes, including T 
lymphocytes (Kayagaki, Yamaguchi et al., 1999), natural killer cells (Smyth, Cretney et al., 
2001), dendritic cells (Vidalain, Azocar et al., 2000; Vidalain, Azocar et al., 2001), monocytes 
and macrophages (Herbeuval, Lambert et al., 2003). TRAIL can activate both intrinsic or 
extrinsic apoptosis pathway. DR4 and DR5 induced apoptosis through the formation of a 
death inducing signaling complex (DISC) containing the death receptor, adaptor proteins 
such as Fas-associated death domain (FADD), and initiator caspases such as pro-caspase-8 
or pro-caspase-10 (Bellail, Tse et al., 2009; Jin, Kurakin et al., 2004; Walczak and Haas, 2008). 
Consequently, pro-caspase-8 or pro-caspase-10 are activated by autoproteolytic processing, 
which then cleave and activate downstream effector caspases (Gomez-Benito, Martinez-
Lorenzo et al., 2007), such as caspase-3 (extrinsic pathway). Additionally, the Bcl-2-
interacting protein Bid is also cleaved by caspase-8. Truncated-Bid causes the loss of 
mitochondrial membrane potential and caspase-9 cleavage, resulting in apoptosis. Very little 
is known concerning death and decoy receptors regulation. Among these receptors, death 
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receptor is the most studied, and authors showed that DR5 transcription is regulated (at 
least partially) by the protooncogene p53 (Sheikh, Burns et al., 1998; Wu, Burns et al., 1997). 
It should be noticed that TRAIL death receptors 4 and 5 not only induce apoptosis but may 
also play a crucial role in inflammatory responses (Collison, Foster et al., 2009). Figure 5 
illustrates TRAIL pathway and regulation.  
TRAIL is a very promising candidate for cancer treatment due to its sophisticated way of 
inducing apoptosis. While the vast majority of  normal cells express decoy receptors and are 
therefore protected from TRAIL-mediated apoptosis, tumor cells generally express death 
receptors. Indeed, TRAIL induces apoptosis in human tumor cell lines (Griffith, Chin et al., 
1998) but not in normal cells (Gura, 1997). TRAIL also induces apoptosis of infected cells. 
For example, plasma TRAIL has been reported to be an early pathogenic marker in acute 
HIV-1 infection and is correlated to viral load in chronic disease (Gasper-Smith, Crossman et 
al., 2008; Herbeuval, Nilsson et al., 2009). HIV-1 upregulates DR5 expression on the 
membrane of CD4+ T cells in vitro (Herbeuval, Boasso et al., 2005; Herbeuval, Grivel et al., 
2005) making them prone to TRAIL-mediated apoptosis (Lichtner, Maranon et al., 2004). 
Furthermore, the percentage of CD4+ T cells co-expressing TRAIL and DR5 are elevated in 
the blood of viremic progressors (Herbeuval, Grivel et al., 2005). Thus, TRAIL does not 
exhibit cytotoxic effects on normal cells and tissues and is potentially efficient to eradicate a 
large panel of cancer cells. Several clinical trial are currently evaluating TRAIL anti tumor 
effect, alone or in combination with other chemotherapeutic drugs.  
Thus, it remained pertinent to determine whether ATL cells were sensitive to TRAIL-
mediated apoptosis. One study characterized the sensitivity of ATL cells to TRAIL 
cytotoxicity. Authors tested several cell lines and also primary cells from both chronic and 
acute ATL. Unfortunately, the vast majority of primary ATL cells or cell lines appears to be 
resistant to TRAIL induced cell death (Matsuda, Almasan et al., 2005). This resistance was 
due to multiple parameters, including the lack of DR4 and DR5 expression, abrogation of 
death signal upstream caspase-8, attenuation of both extrinsic and intrinsic apoptotic 
pathways. More recently, it has been shown that the resistance upstream caspase 8 was due 
to an over expression of the cellular caspase-8 (FLICE)-inhibitory protein (c-FLIP) that 
blocks caspase recruitment and apoptosis. However, other study show that ATL cells might 
be sensitive to TRAIL-induced apoptosis (Hasegawa, Yamada et al., 2005), therefore TRAIL 
effect in ATL should be clarified. 
Surprisingly, most of ATL cells expressed TRAIL on their surface. This finding suggested 
that constitutive expression of TRAIL would participate in the development of TRAIL-
resistant clones observed in patients. The natural resistance of ATL cells would have 
excluded the use of TRAIL as therapeutic agent. However, a recent study demonstrated that 
the herbal compound Rocaglamide restores TRAIL sensibility in ATL cells. Indeed, 
Rocaglamide induces suppression of c-FLIP expression in ATL cells that sensitizes these 
cells to TRAIL-mediated apoptosis. Authors suggest the use of Rocaglamide as an adjuvant 
to TRAIL as new therapeutic strategies against HTLV-1-mediated ATL (Bleumink, Kohler et 
al.). It has also been observed that the use of a combination of a p53 activator, Nutlin-3a, and 
TRAIL synergized to induce ATL cell apoptosis (Hasegawa, Yamada et al., 2009). This could 
be explained by the fact that p53 regulates TRAIL death receptor 5 on cell surface. Thus, 
Nutlin-3a treated ATL cells would express DR5 and then become sensitive to TRAIL-
mediated apoptosis. 
Therefore, the understanding of ATL sensitivity to TRAIL-mediated apoptosis appears to be 
crucial to develop new therapeutic options.  
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Fig. 5. TRAIL apoptotic pathway. Membrane (mTRAIL) or soluble TRAIL (sTRAIL) bind to 
3 decoy receptors (DcR1, DcR2 and OPG) and 2 death receptors (DR4 and DR5) which 
activate the caspase pathway leading to apoptosis.  
4.3 Myeloid dendritic cells and HTLV-1 infection 
HTLV-1 targets CD4+ T cells which represent an important target for HTLV-1 infection in 
the peripheral blood. However, there are some additional evidence that showed that HTLV-
1 can also infect including CD8+ T lymphocytes, monocytes, B lymphocytes, astrocytes 
(Richardson, Edwards et al., 1990) and dendritic cells (DC) in vivo. Myeloid dendritic cells 
do not exhibit high viral gene expression, but recent work suggested that HTLV-1-infected 
dendritic cells show better capacity to stimulate antigen-specific T cell activation (Makino, 
Shimokubo et al., 1999). Moreover, the proportion of lymphoid organs containing HTLV-1 
positive dendritic cells is proportional to the total proviral DNA load in the blood, 
providing a correlation of proviral DNA load and the frequency of effector/memory Tax- 
CD8+ T cells (Nagai, Kubota et al., 2001).  
More recently, findings demonstrated a central role to myeloid dendritic (mDC) and 
plasmacytoid dendritic cells (pDC)  in HTLV-1 infection. For years it has been thought that 
unlike other retroviruses such as HIV-1, free virions were poorly infectious (Donegan, Lee et 
al., 1994). However, a recent study reported that freshly isolated mDC and pDC are 
efficiently and productively infected by cell-free HTLV-1 (Jones, Petrow-Sadowski et al., 
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2008). Furthermore, infected mDC and pDC were able to transfer virions to autologous 
CD4+ T cells, clearly demonstrating that cell free HTLV-1 can be infectious and target 
dendritic cells (Jones, Petrow-Sadowski et al., 2008). 
5. HTLV-1 and plasmacytoid dendritic cell response 
Plasmacytoid dendritic cells were discovered in 1997 as professional IFN-alpha producers 
and innate immune cells (Grouard, Rissoan et al., 1997). These cells are rare but play a 
central role in host defense against viruses and bacteria by producing cytokines and 
antiviral factors. The role of pDC in HTLV-1 infection remained unknown until recent years 
probably because of the extreme difficulty of studying HTLV-1 acute infection. We describe 
here recent data providing some new features in the understanding of HTLV-1 innate 
immune response.  
5.1 The Plasmacytoid dendritic cell (pDC) 
PDC are cells of hemopoietic origin that are found at steady state in the blood, thymus and 
peripheral lymphoid tissues. Early studies described pDC as being oval-shaped with typical 
plasmacytoid morphology. The ability of plasmacytoid-derived DC (also named DC2) to 
induce a Th2 differentiation of naïve CD4 T cells formed the basis for the concept of type 1 
and type 2 DC (Review Nat immunol, 2001). The role of these DC in mouse and human was 
studied in different models and is not completely elucidated (Liu, 2005). A little later, it was 
shown that pDC were specialized in the production of type I IFN (Siegal, Kadowaki et al., 
1999). They are the principal source of type I IFN in human blood and very rapidly produce 
all type I IFN isoforms in response to microbial stimuli, such as virus (Cella, Jarrossay et al., 
1999; Siegal, Kadowaki et al., 1999), CpG-containing oligonucleotides (Kadowaki, 
Antonenko et al., 2000), or the synthetic molecules imidazoquinolines (Gibson, Lindh et al., 
2002). PDC-derived type I IFN has direct anti-viral activity against a variety of virus, 
including HIV, and has important adjuvant functions on other immune cell-types, such as 
NK cells, T cells, macrophages and DC. Thus, pDC activation triggers a dual type of 
response: type I IFN production and DC differentiation (Colonna, Trinchieri et al., 2004; 
Yang, Lian et al., 2005). 
PDC and plasmacytoid-derived DC express the Toll-Like receptor TLR7 and TLR9 
(Jarrossay, Napolitani et al., 2001; Kadowaki and Liu, 2002) and respond to their respective 
ligands, imidazoquinolines (Hemmi, Kaisho et al., 2002) and single strand RNA (Diebold, 
Kaisho et al., 2004; Heil, Hemmi et al., 2004; Lund, Alexopoulou et al., 2004) for TLR7, CpG-
containing oligonucleotides (Hemmi, Takeuchi et al., 2000) and DNA viruses (Lund, Sato et 
al., 2003) for TLR9. They do not express TLR2, TLR3 and TLR4, and do not respond to such 
ligands as peptidoglycan, LPS (lipopolysaccharides) or double-stranded RNA (Jarrossay, 
Napolitani et al., 2001; Kadowaki and Liu, 2002). Activation of pDC through TLR7 and TLR9 
can trigger both types of response, including large quantities of type I IFN production 
and/or DC differentiation (Liu, 2005). Synthetic CpG-containing oligonucleotides of the 
types A and B (CpG-A, CpG-B) selectively induce type I IFN production and DC 
differentiation, respectively (Duramad, Fearon et al., 2005) while some viral stimuli, such as 
influenza virus (Flu), herpes simplex virus (HSV) or CpG-C can induce simultaneously both 
responses (Liu, 2005). Two factors seem to be key for the induction of large quantities of 
type I IFN in pDC: 1) the ability of the TLR ligands to bind its receptor in the early 
endosomal compartments (Guiducci, Ott et al., 2006; Honda, Ohba et al., 2005); 2) the 
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phosphorylation and nuclear translocation of the transcription factor IRF-7 (Honda, Yanai et 
al., 2005). This last step was shown to depend on the kinases IRAK-1 (Uematsu, Sato et al., 
2005) and IkB kinase-a (IKK-a) (Hoshino, Sugiyama et al., 2006) in mouse pDC. It has been 
recently shown that the PI3-kinase pathway was critical to control the nuclear translocation 
of IRF-7 and the subsequent production of type I IFN (Guiducci, Ghirelli et al., 2008). At the 
present time, it is not known whether additional molecular pathways are involved and 
modulated HTLV-1 diseases.  
PDC express a panel of surface receptors but their function remain largely unknown. The 
best characterized is the lectin BDCA-2 (Blood dendritic cell antigen-2) (Dzionek, Inagaki et 
al., 2002; Dzionek, Sohma et al., 2001). BDCA-2 mediates antigen uptake and inhibits pDC 
production of type 1 IFN induced by influenza virus (Dzionek, Sohma et al., 2001). This 
inhibition is mediated by the induction of a B cell receptor-like signaling cascade (Cao, 
Zhang et al., 2007). Neuropilin 1 (NRP1), also called BDCA-4, is another surface receptor 
constitutively expressed at high levels on human pDC. NRP1 is involved in the interaction 
between myeloid DC and T cells within the immune synapse (Tordjman, Lepelletier et al., 
2002). However, its role in pDC function remains unknown. Recently, we have shown that 
NRP1 was a coreceptor for the HTLV-1 virus and might be involved in viral entry (Ghez, 
Lepelletier et al., 2006). Thus HTLV-1 could provide a link between the molecular pathways 
downstream of NRP1 and the physiopathology of pDC in HTLV-related diseases. 
There is increasing evidence that pDC are involved in several disease settings. They were 
observed in situ in a variety of pathological conditions, such as HPV-related cervical cancer, 
skin melanoma (Salio, Cella et al., 2003), psoriasis (Nestle, Conrad et al., 2005) or allergic 
contact dermatitis (Bangert, Friedl et al., 2003) and in the nasal mucosa as early as 6 hours 
after allergen challenge, suggesting an active recruitment of blood pDC at the site of 
inflammation. Moreover, a dysregulated TLR-induced IFN response has been linked to 
autoimmune diseases (Colonna, 2006; Marshak-Rothstein, 2006), particularly lupus 
erythematosus and psoriasis (Nestle, Conrad et al., 2005). 
5.2 pDC and HTLV-1 infection 
Three molecules have been characterized for HTLV-1 entry into cells, heparin sulfate 
proteoglycans (HSPG) (Jones, Petrow-Sadowski et al., 2005) and NRP-1 (also called BDCA-4) 
for the initial virus binding to target cells (Ghez, Lepelletier et al., 2006), and glucose 
transporter 1 (GLUT-1) for the post-attachment and the viral fusion (Manel, Kim et al., 2003; 
Takenouchi, Jones et al., 2007). Interestingly, NRP-1 is expressed by mDC and T cells but 
cells expressing the highest level of BDCA-4 in blood are pDC (Grouard, Rissoan et al., 1997; 
Siegal, Kadowaki et al., 1999), strongly suggesting that HTLV-1 could interact with pDC. 
Nevertheless, HTLV-1-induced immune response by professional “sentinel” pDC has not 
been reported. Viral activation of pDC can be regulated by either of two Toll-like Receptors 
(TLR), TLR7 or TLR9, which are considered to be the receptors that human pDC use for 
recognition of RNA/retroviruses and DNA, respectively. HIV-activated pDC were recently 
reported to express the tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) (Chaperot, Blum et al., 2006; Hardy, Graham et al., 2007; Stary, Klein et al., 2009). 
TRAIL has been shown to induce apoptosis of cancer (Herbeuval, Lambert et al., 2003; 
Walczak, Miller et al., 1999) and infected cells expressing death receptor-4 or -5 (DR4, DR5). 
We recently demonstrated that HTLV-1 stimulated pDC expressed TRAIL and acquired 
cytotoxic activity, transforming them into a new subset of killer innate immune cells, which 
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may play a central role in viral immunopathogenesis and tumor development (Hardy, 
Graham et al., 2007).  
The role of pDC in HTLV-1 infection was unknown until Jones et al reported that freshly 
purified mDC and pDC could be productively infected by HTLV-1 free viruses (Jones, 
Petrow-Sadowski et al., 2008). Authors clearly demonstrated that infected pDC and mDC 
could also infect CD4+ T cells in vitro. These findings were major discovery for two reasons: 
first, they showed that, unlike researcher thought for years, free particles of HTLV-1 could 
directly infect T cells, and secondly because it was the first demonstration of pDC-HTLV-1 
interaction.  
However, the infection of target cells by HTLV-1 is not totally understood and need to be 
clarified. HTLV-1 infection is a sequential process that potentially involves the recruitment 
of at least three molecules. 
5.3 pDC activation by cell free HTLV-1 virions 
Due to abvious evidences that pDC and HTLV-1 could interact, we decided to study pDC 
response against HTLV-1. The first parameter we tested was the IFN- production, which is 
characteristic of the innate immune response. Our first results were disappointing. Using 
supernatants from chronically HTLV-1-infected cell lines we stimulated pDC in vitro. The IFN-
 produced by pDC exposed to supernatants from MT-2 cell line remained very low compared 
to Influenza A (Flu) stimulation. The difference between the two stimulation was the purity of 
the viruses: Flu was a purified virus while HTLV-1 stimulation was made from supernatants. 
Thus, we decided to purify HTLV-1 by ultracentrifugation. Pelets were collected and the 
quantity of viruses was determined using p19 ELISA. Thus, we could calculate the 
concentration of purified HTLV-1 and use a large range of viral concentration to stimulate 
pDC. Therefore, we showed that purified cell free HTLV-1 particles could induce massive IFN-
 by pDC, similarly to Influenza A virus (Flu) or HIV stimulation. For the first time, we clearly 
demonstrated that free HTLV-1 particles, as other retroviruses, could generate an IFN- 
response by pDC (Colisson, Barblu et al, 2010). We also tested IL-10 and TNF- production by 
HTLV-1-exposed pDC and found high levels of IL-10 and TNF- production.  
We and others reported that Flu or HIV-1 activation of pDC resulted in cytokine production 
but also activation markers (CD40, HLADR), maturation markers (CD80, CD86) and 
migration marker CCR7 (Beignon, McKenna et al., 2005; Chaperot, Blum et al., 2006; 
Fonteneau, Larsson et al., 2004). We found that HTLV-1, like other retroviruses, induced 
activation and maturation marker expression by pDC. However, it remained unclear 
whether the lymphoid migration marker CCR7 was expressed by pDC after HTLV-1 
exposure. This might have essential consequences in immunopathogenesis. Indeed, HIV-1 
induces migration of pDC from the blood to lymphoid organs by upregulating CCR7 
expression on cell surface. Thus, activated pDC migrate to tonsils and other lymphoid 
organs and participate to CD4+ T cell depletion in tissues (Stary, Klein et al., 2009). We 
observed that CCR7 was not or weakly expressed by pDC after HTLV-1 exposure. 
Consequently, we could imagine that pDC do not migrate to lymphoid tissues in HTLV-1 
infected patients, in contrast to HIV-1 patients. Further studies are needed to better 
characterized in vitro and in vivo CCR7 expression and pDC migration in patients. 
We next wanted to better characterize pDC activation by HTLV-1. We previously reported 
that HIV-1 induced pDC transformation into TRAIL-expressing pDC, which were able to 
induce apoptosis of CD4+ T cells expressing DR5  (Hardy, Graham et al., 2007). This new 
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subset of killer cells was called Interferon-producing Killer pDC (ie IKpDC). Using cell free 
purified HTLV-1 particles, we stimulated isolated pDC from healthy donors and cells were 
analyzed using three dimensional (3D) microscopy. Microscopy revealed some surprising 
results. We found high levels of TRAIL in non activated pDC. This result was not expected 
as it has never been observed before. However, it was not clear whether TRAIL was located 
on membrane or in cytoplasm. Thus, using the ImageJ tool "3D interactive surface plot", we 
demonstrated that TRAIL was located in the cytoplasm of resting pDC (Colisson, Barblu et 
al.). In contrast, HTLV-1 stimulated pDC showed a relocalization of TRAIL from cytoplasm 
to plasma membrane (Figure 6). HTLV-1 exposure induced a relocalization of intracellular 
stock of TRAIL to the membrane, conferring a killer activity to pDC. Surprinsingly, we did 
not detect HTLV-1 viruses in pDC. However, chloroquine treated pDC revealed some 
HTLV-1 particles in cytoplasm. In fact, this latest result provides some indication concerning 
the pathway by which HTLV-1 particles activate pDC.  
 
 
Fig. 6. 3D microscopy of HTLV-1 activated pDC. 3D interactive surface plot was used to 
precisely delimitated TRAIL in pDC. Upper picture show intracellular TRAIL (green) inside 
pDC plasma membrane. Bottom picture shows TRAIL relocalization to the membrane that 
appears green in HTLV-1 exposed pDC. HTLV-1 viruses (red) binds to plasma cell 
membrane. Adapated from Colisson, Barblu et al 2010. 
5.4 HTLV-1 activated endocytosis pathway in pDC 
Because pDC express high levels of NRP-1, which is a member of the HTLV-1 complex 
receptor, they may be productively infected by HTLV-1. However, pDC could aslo activate 
the endocytosis pathway under viral exposure. Endocytosis pathway is charcaterized by 
formation of endosomes in which pH get low activating multiple protease. Viral particles 
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viral RNA or DNA activate their respective receptors TLR7 or TLR9. Chloroquine inhibits 
endocytosis by reducing pH acidification in endosomes.  
We demonstrated using chloroquine and TLR7 inhibitor that HTLV-1 activated the 
endocytosis pathway in pDC as demonstrated for other retrovirus like HIV-1 (Beignon, 
McKenna et al., 2005; Hardy, Graham et al., 2007). Viral particles, after initial binding to 
HTLV-1 receptor complex, entered into the endosome, which became pH low. This 
acidification activates endosomal protease that destroyed virus envelop and capsid, leading 
to single strand RNA (ssRNA) release into the vesicles. This viral ssRNA activates TLR7, 
which in turn recrutes the adaptor protein MyD88, a central molecule in most of TLR-
dependent. The recruitment of MyD88 starts a cascade of activation leading to IFN- 
production (due to the recruitment of Inteferon Regulatory  factor 7, IRF7). We also showed 
that TRAIL expression, activation markers (CD40, HLADR) and maturation markers (CD80, 
CD86) were regulated by TLR7 activation in pDC. These results place TLR7 as the central 
molecule of HTLV-1-induced pDC response (Figure 7). Thus, endocytosis seems to be the 
major pathway involved in pDC activation by HTLV-1. However, it should be noticed that 
our findings do not exclude the possibility that pDC could get productively infected. Our 
study focused on short time experiments that did not allow us to detect newly synthesized 
viruses. Jones et al showed that coculture of mDC and pDC with HTLV-1 could induce 
CD4+ T cell infection, while free viruses alone could not infect T cells (Jones, Petrow-
Sadowski et al., 2008). Further experiments are needed to determine what is the proportion 
of infected pDC versus activated IKpDC.  
 
 
Fig. 7. Transformation of pDC into IKpDC by HTLV-1.  
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6. Conclusion  
Adult T cell leukemia induced by HTLV-1 infection exhibits diverse clinical features. The 
outcome is directly correlated to ATL subtype, that could range from a very indolent and 
slowly progressive lymphoma to a very aggressive and nearly uniformaly lethal 
proliferative lymphoma. Thus, knowledge about HTLV-1 infection and propagation remains 
essential to better understand pathogenesis consequences.  
An important challenge would be to link the pDC phenotype to the different HTLV-1 
associated pathologies (ATLL). It would be interesting to determine whether IKpDC persist 
during chronic infection in order to generate new HTLV-1 progression markers. The 
characterization of IKpDC in vivo opens new area of dendritic cells research in HTLV-1 and 
other retrovirus-induced immunopathogenesis and in tumor cell biology. Considered 
together, our data highlight a dual role for pDC in HTLV-1 disease. pDC that become  
infected may participate in viral spread in the host (Jones, Petrow-Sadowski et al., 2008) and 
concomitantly express TRAIL, which may select the transformed CD4+ T cell clone, leading 
to ATLL years later. In this context, it will be of great interest to test TRAIL sensitivity of the 
persistent clones after HTLV-1 infection that may subsequently be transformed to 
lymphoma/leukemia. Thus, pDC investigation in HTLV-1 disease will be crucial for 
understanding complex HTLV-1-associated pathologies. However, detection of primary 
infection in humans is currently not feasible due to the high latency of HTLV-1 virus before 
disease symptoms appearance. An alternative way to characterize and understand the early 
steps of HTLV-1 infection is the development of the pathogenic simian model (STLV-1). 
However, in addition to selection of TRAIL-resistant clones, one could hypothesize that 
similar to HIV-1 infection, pDC may participate in and contribute to the immune 
suppression that occurs in ATLL. 
HTLV-1 free particles generate an immune response by professional virus “sentinel” pDC. 
We then identify and describe the mechanism by which purified HTLV-1 virions stimulate 
pDC and transform them into functional killer cells. We show that pDC response and 
activation to HTLV-1 is strictly virus-dose dependent. Finally, purified HTLV-1 particles 
induced TLR7-mediated relocalization of intracellular TRAIL to the pDC membrane. In 
conclusion, the physiological function of pDC during the different stages of HTLV-1 
infection will represent a new field of investigation and may lead to new therapeutic 
strategies. 
7. Acknowledgment  
 I would like to thank Pr Olivier Hermine, UMR 8147 Hopital Necker, Paris, for his precious 
advice and critics and Lucie Barblu for helping me on this manuscript.  
8. References  
Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of immunity." 
Nature 392 (6673): 245-52 
Bangert, C., J. Friedl, et al. (2003). "Immunopathologic features of allergic contact dermatitis 
in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the 
disease?" J Invest Dermatol 121 (6): 1409-18 
www.intechopen.com
 T-Cell Leukemia 
 
18
Beignon, A. S., K. McKenna, et al. (2005). "Endocytosis of HIV-1 activates plasmacytoid 
dendritic cells via Toll-like receptor- viral RNA interactions." J Clin Invest 
Bellail, A. C., M. C. Tse, et al. (2009). "DR5-mediated DISC controls caspase-8 cleavage and 
initiation of apoptosis in human glioblastomas." J Cell Mol Med 
Bleumink, M., R. Kohler, et al. "Rocaglamide breaks TRAIL resistance in HTLV-1-associated 
adult T-cell leukemia/lymphoma by translational suppression of c-FLIP 
expression." Cell Death Differ 18 (2): 362-70 
Cao, W., L. Zhang, et al. (2007). "BDCA2/Fc epsilon RI gamma complex signals through a 
novel BCR-like pathway in human plasmacytoid dendritic cells." PLoS Biol 5 (10): 
e248 
Cella, M., D. Jarrossay, et al. (1999). "Plasmacytoid monocytes migrate to inflamed lymph 
nodes and produce large amounts of type I interferon." Nat Med 5 (8): 919-23 
Chaperot, L., A. Blum, et al. (2006). "Virus or TLR agonists induce TRAIL-mediated 
cytotoxic activity of plasmacytoid dendritic cells." J Immunol 176 (1): 248-55 
Colisson, R., L. Barblu, et al. "Free HTLV-1 induces TLR7-dependent innate immune 
response and TRAIL relocalization in killer plasmacytoid dendritic cells." Blood 115 
(11): 2177-85 
Collison, A., P. S. Foster, et al. (2009). "Emerging role of tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses." 
Clin Exp Pharmacol Physiol 36 (11): 1049-53 
Colonna, M. (2006). "Toll-like receptors and IFN-alpha: partners in autoimmunity." J Clin 
Invest 116 (9): 2319-22 
Colonna, M., G. Trinchieri, et al. (2004). "Plasmacytoid dendritic cells in immunity." Nat 
Immunol 5 (12): 1219-26 
de The, G., L. Gazzolo, et al. (1985). "Viruses as risk factors or causes of human leukaemias 
and lymphomas?" Leuk Res 9 (6): 691-6 
Diebold, S. S., T. Kaisho, et al. (2004). "Innate antiviral responses by means of TLR7-
mediated recognition of single-stranded RNA." Science 303 (5663): 1529-31 
Donegan, E., H. Lee, et al. (1994). "Transfusion transmission of retroviruses: human T-
lymphotropic virus types I and II compared with human immunodeficiency virus 
type 1." Transfusion 34 (6): 478-83 
Duramad, O., K. L. Fearon, et al. (2005). "Inhibitors of TLR-9 act on multiple cell subsets in 
mouse and man in vitro and prevent death in vivo from systemic inflammation." 
Journal of immunology (Baltimore, Md.: 1950) 174 (9): 5193-5200 
Dzionek, A., Y. Inagaki, et al. (2002). "Plasmacytoid dendritic cells: from specific surface 
markers to specific cellular functions." Hum Immunol 63 (12): 1133-48 
Dzionek, A., Y. Sohma, et al. (2001). "BDCA-2, a novel plasmacytoid dendritic cell-specific 
type II C-type lectin, mediates antigen capture and is a potent inhibitor of 
interferon alpha/beta induction." J Exp Med 194 (12): 1823-34 
Ehrlich, S., C. Infante-Duarte, et al. (2003). "Regulation of soluble and surface-bound TRAIL 
in human T cells, B cells, and monocytes." Cytokine 24 (6): 244-53 
Fonteneau, J. F., M. Larsson, et al. (2004). "Human immunodeficiency virus type 1 activates 
plasmacytoid dendritic cells and concomitantly induces the bystander maturation 
of myeloid dendritic cells." J Virol 78 (10): 5223-32 
www.intechopen.com
 Adult Human T Cell Leukemia 
 
19 
Fujino, T. and Y. Nagata (2000). "HTLV-I transmission from mother to child." J Reprod 
Immunol 47 (2): 197-206 
Gasper-Smith, N., D. M. Crossman, et al. (2008). "Induction of plasma (TRAIL), TNFR-2, Fas 
ligand, and plasma microparticles after human immunodeficiency virus type 1 
(HIV-1) transmission: implications for HIV-1 vaccine design." J Virol 82 (15): 
7700-10 
Gessain, A., F. Barin, et al. (1985). "Antibodies to human T-lymphotropic virus type-I in 
patients with tropical spastic paraparesis." Lancet 2 (8452): 407-10 
Ghez, D., Y. Lepelletier, et al. "Current concepts regarding the HTLV-1 receptor complex." 
Retrovirology 7: 99 
Ghez, D., Y. Lepelletier, et al. (2006). "Neuropilin-1 is involved in human T-cell 
lymphotropic virus type 1 entry." J Virol 80 (14): 6844-54 
Gibson, S. J., J. M. Lindh, et al. (2002). "Plasmacytoid dendritic cells produce cytokines and 
mature in response to the TLR7 agonists, imiquimod and resiquimod." Cell Immunol 
218 (1-2): 74-86 
Gomez-Benito, M., M. J. Martinez-Lorenzo, et al. (2007). "Membrane expression of DR4, DR5 
and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells 
to Apo2L/TRAIL." Exp Cell Res 313 (11): 2378-88 
Grabbe, S., E. Kampgen, et al. (2000). "Dendritic cells: multi-lineal and multi-functional." 
Immunol Today 21 (9): 431-3 
Griffith, T. S., W. A. Chin, et al. (1998). "Intracellular regulation of TRAIL-induced apoptosis 
in human melanoma cells." J Immunol 161 (6): 2833-40 
Grouard, G., M. C. Rissoan, et al. (1997). "The enigmatic plasmacytoid T cells develop into 
dendritic cells with interleukin (IL)-3 and CD40-ligand." J Exp Med 185 (6): 1101-11 
Grumont, R. J. and S. Gerondakis (2000). "Rel induces interferon regulatory factor 4 (IRF-4) 
expression in lymphocytes: modulation of interferon-regulated gene expression by 
rel/nuclear factor kappaB." J Exp Med 191 (8): 1281-92 
Guiducci, C., C. Ghirelli, et al. (2008). "PI3K is critical for the nuclear translocation of IRF-7 
and type I IFN production by human plasmacytoid predendritic cells in response to 
TLR activation." J Exp Med 
Guiducci, C., G. Ott, et al. (2006). "Properties regulating the nature of the plasmacytoid 
dendritic cell response to Toll-like receptor 9 activation." J Exp Med 203 (8): 
1999-2008 
Gura, T. (1997). "How TRAIL kills cancer cells, but not normal cells." Science 277 (5327): 768 
Hardy, A. W., D. R. Graham, et al. (2007). "HIV turns plasmacytoid dendritic cells (pDC) 
into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like 
receptor 7-induced IFN-alpha." Proc Natl Acad Sci U S A 104 (44): 17453-8 
Hasegawa, H., Y. Yamada, et al. (2005). "Sensitivity of adult T-cell leukaemia lymphoma 
cells to tumour necrosis factor-related apoptosis-inducing ligand." Br J Haematol 128 
(2): 253-65 
Hasegawa, H., Y. Yamada, et al. (2009). "Activation of p53 by Nutlin-3a, an antagonist of 
MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells." 
Leukemia 23 (11): 2090-101 
www.intechopen.com
 T-Cell Leukemia 
 
20
Heil, F., H. Hemmi, et al. (2004). "Species-specific recognition of single-stranded RNA via 
toll-like receptor 7 and 8." Science 303 (5663): 1526-9 
Hemmi, H., T. Kaisho, et al. (2002). "Small anti-viral compounds activate immune cells via 
the TLR7 MyD88-dependent signaling pathway." Nat Immunol 3 (2): 196-200 
Hemmi, H., O. Takeuchi, et al. (2000). "A Toll-like receptor recognizes bacterial DNA." 
Nature 408 (6813): 740-5 
Herbeuval, J. P., A. Boasso, et al. (2005). "TNF-related apoptosis-inducing ligand (TRAIL) in 
HIV-1-infected patients and its in vitro production by antigen-presenting cells." 
Blood 105 (6): 2458-64 
Herbeuval, J. P., J. C. Grivel, et al. (2005). "CD4+ T-cell death induced by infectious and 
noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated 
apoptosis." Blood 106 (10): 3524-31 
Herbeuval, J. P., C. Lambert, et al. (2003). "Macrophages From Cancer Patients: Analysis of 
TRAIL, TRAIL Receptors, and Colon Tumor Cell Apoptosis." J Natl Cancer Inst 95 
(8): 611-621 
Herbeuval, J. P., J. Nilsson, et al. (2009). "HAART reduces death ligand but not death 
receptors in lymphoid tissue of HIV-infected patients and simian 
immunodeficiency virus-infected macaques." Aids 23 (1): 35-40 
Hermine, O., D. Bouscary, et al. (1995). "Brief report: treatment of adult T-cell leukemia-
lymphoma with zidovudine and interferon alfa." N Engl J Med 332 (26): 1749-51 
Hermine, O., H. Dombret, et al. (2004). "Phase II trial of arsenic trioxide and alpha interferon 
in patients with relapsed/refractory adult T-cell leukemia/lymphoma." Hematol J 5 
(2): 130-4 
Hinuma, Y., Y. Gotoh, et al. (1982). "A retrovirus associated with human adult T-cell 
leukemia: in vitro activation." Gann 73 (2): 341-4 
Honda, K., Y. Ohba, et al. (2005). "Spatiotemporal regulation of MyD88-IRF-7 signalling for 
robust type-I interferon induction." Nature 434 (7036): 1035-40 
Honda, K., H. Yanai, et al. (2005). "IRF-7 is the master regulator of type-I interferon-
dependent immune responses." Nature 434 (7034): 772-7 
Hoshino, K., T. Sugiyama, et al. (2006). "IkappaB kinase-alpha is critical for interferon-alpha 
production induced by Toll-like receptors 7 and 9." Nature 440 (7086): 949-953 
Imaizumi, Y., T. Kohno, et al. (2001). "Possible involvement of interferon regulatory factor 4 
(IRF4) in a clinical subtype of adult T-cell leukemia." Jpn J Cancer Res 92 (12): 
1284-92 
Imura, A., T. Hori, et al. (1997). "OX40 expressed on fresh leukemic cells from adult T-cell 
leukemia patients mediates cell adhesion to vascular endothelial cells: implication 
for the possible involvement of OX40 in leukemic cell infiltration." Blood 89 (8): 
2951-8 
Jacobson, S. (1996). "Cellular immune responses to HTLV-I: immunopathogenic role in 
HTLV-I-associated neurologic disease." J Acquir Immune Defic Syndr Hum Retrovirol 
13 Suppl 1: S100-6 
Jarrossay, D., G. Napolitani, et al. (2001). "Specialization and complementarity in microbial 
molecule recognition by human myeloid and plasmacytoid dendritic cells." Eur J 
Immunol 31 (11): 3388-93 
www.intechopen.com
 Adult Human T Cell Leukemia 
 
21 
Jin, T. G., A. Kurakin, et al. (2004). "Fas-associated protein with death domain (FADD)-
independent recruitment of c-FLIPL to death receptor 5." J Biol Chem 279 (53): 
55594-601 
Jones, K. S., C. Petrow-Sadowski, et al. (2005). "Heparan sulfate proteoglycans mediate 
attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T 
cells." J Virol 79 (20): 12692-702 
Jones, K. S., C. Petrow-Sadowski, et al. (2008). "Cell-free HTLV-1 infects dendritic cells 
leading to transmission and transformation of CD4(+) T cells." Nat Med 14 (4): 
429-36 
Kadowaki, N., S. Antonenko, et al. (2000). "Natural interferon alpha/beta-producing cells 
link innate and adaptive immunity." J Exp Med 192 (2): 219-26 
Kadowaki, N. and Y. J. Liu (2002). "Natural type I interferon-producing cells as a link 
between innate and adaptive immunity." Hum Immunol 63 (12): 1126-32 
Kayagaki, N., N. Yamaguchi, et al. (1999). "Involvement of TNF-related apoptosis-inducing 
ligand in human CD4+ T cell-mediated cytotoxicity." J Immunol 162 (5): 2639-47 
Kohno, T., R. Moriuchi, et al. (2000). "Identification of genes associated with the progression 
of adult T cell leukemia (ATL)." Jpn J Cancer Res 91 (11): 1103-10 
Koyanagi, Y., Y. Itoyama, et al. (1993). "In vivo infection of human T-cell leukemia virus type 
I in non-T cells." Virology 196 (1): 25-33 
Kunitomi, A., T. Hori, et al. (2002). "OX40 signaling renders adult T-cell leukemia cells 
resistant to Fas-induced apoptosis." Int J Hematol 76 (3): 260-6 
Lambert, S., M. Bouttier, et al. (2009). "HTLV-1 uses HSPG and neuropilin 1 for entry by 
molecular mimicry of VEGF165." Blood 
Lichtner, M., C. Maranon, et al. (2004). "HIV type 1-infected dendritic cells induce apoptotic 
death in infected and uninfected primary CD4 T lymphocytes." AIDS Res Hum 
Retroviruses 20 (2): 175-82 
Liu, Y. J. (2005). "IPC: professional type 1 interferon-producing cells and plasmacytoid 
dendritic cell precursors." Annu Rev Immunol 23: 275-306 
Lund, J., A. Sato, et al. (2003). "Toll-like receptor 9-mediated recognition of Herpes simplex 
virus-2 by plasmacytoid dendritic cells." J Exp Med 198 (3): 513-20 
Lund, J. M., L. Alexopoulou, et al. (2004). "Recognition of single-stranded RNA viruses by 
Toll-like receptor 7." Proc Natl Acad Sci U S A 101 (15): 5598-603 
Macatonia, S. E., J. K. Cruickshank, et al. (1992). "Dendritic cells from patients with tropical 
spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte 
proliferation." AIDS Res Hum Retroviruses 8 (9): 1699-706 
Makino, M., S. Shimokubo, et al. (1999). "The role of human T-lymphotropic virus type 1 
(HTLV-1)-infected dendritic cells in the development of HTLV-1-associated 
myelopathy/tropical spastic paraparesis." J Virol 73 (6): 4575-81 
Mamane, Y., N. Grandvaux, et al. (2002). "Repression of IRF-4 target genes in human T cell 
leukemia virus-1 infection." Oncogene 21 (44): 6751-65 
Mamane, Y., M. Loignon, et al. (2005). "Repression of DNA repair mechanisms in IRF-4-
expressing and HTLV-I-infected T lymphocytes." J Interferon Cytokine Res 25 (1): 
43-51 
www.intechopen.com
 T-Cell Leukemia 
 
22
Manel, N., F. J. Kim, et al. (2003). "The ubiquitous glucose transporter GLUT-1 is a receptor 
for HTLV." Cell 115 (4): 449-59 
Manns, A., W. J. Miley, et al. (1999). "Quantitative proviral DNA and antibody levels in the 
natural history of HTLV-I infection." J Infect Dis 180 (5): 1487-93 
Mansky, L. M. (2000). "In vivo analysis of human T-cell leukemia virus type 1 reverse 
transcription accuracy." J Virol 74 (20): 9525-31 
Marshak-Rothstein, A. (2006). "Toll-like receptors in systemic autoimmune disease." Nat Rev 
Immunol 6 (11): 823-35 
Matsuda, T., A. Almasan, et al. (2005). "Resistance to Apo2 ligand (Apo2L)/tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and 
constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-
infected T-cell lines." J Virol 79 (3): 1367-78 
Matsuoka, M. (2005). "Human T-cell leukemia virus type I (HTLV-I) infection and the onset 
of adult T-cell leukemia (ATL)." Retrovirology 2: 27 
Mortreux, F., I. Leclercq, et al. (2001). "Somatic mutation in human T-cell leukemia virus 
type 1 provirus and flanking cellular sequences during clonal expansion in vivo." J 
Natl Cancer Inst 93 (5): 367-77 
Mueller, N., A. Okayama, et al. (1996). "Findings from the Miyazaki Cohort Study." J Acquir 
Immune Defic Syndr Hum Retrovirol 13 Suppl 1: S2-7 
Nagai, M., R. Kubota, et al. (2001). "Increased activated human T cell lymphotropic virus 
type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with 
HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with 
HTLV-I provirus load." J Infect Dis 183 (2): 197-205 
Nestle, F. O., C. Conrad, et al. (2005). "Plasmacytoid predendritic cells initiate psoriasis 
through interferon-alpha production." J Exp Med 202 (1): 135-43 
Pais-Correia, A. M., M. Sachse, et al. "Biofilm-like extracellular viral assemblies mediate 
HTLV-1 cell-to-cell transmission at virological synapses." Nat Med 16 (1): 83-9 
Poiesz, B. J., F. W. Ruscetti, et al. (1980). "T-cell lines established from human T-lymphocytic 
neoplasias by direct response to T-cell growth factor." Proc Natl Acad Sci U S A 77 
(11): 6815-9 
Poiesz, B. J., F. W. Ruscetti, et al. (1981). "Isolation of a new type C retrovirus (HTLV) in 
primary uncultured cells of a patient with Sezary T-cell leukaemia." Nature 294 
(5838): 268-71 
Proietti, F. A., A. B. Carneiro-Proietti, et al. (2005). "Global epidemiology of HTLV-I infection 
and associated diseases." Oncogene 24 (39): 6058-68 
Pulendran, B., K. Palucka, et al. (2001). "Sensing pathogens and tuning immune responses." 
Science 293 (5528): 253-6 
Richardson, J. H., A. J. Edwards, et al. (1990). "In vivo cellular tropism of human T-cell 
leukemia virus type 1." J Virol 64 (11): 5682-7 
Robert-Guroff, M., Y. Nakao, et al. (1982). "Natural antibodies to human retrovirus HTLV in 
a cluster of Japanese patients with adult T cell leukemia." Science 215 (4535): 975-8 
Salio, M., M. Cella, et al. (2003). "Plasmacytoid dendritic cells prime IFN-gamma-secreting 
melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions." 
Eur J Immunol 33 (4): 1052-62 
www.intechopen.com
 Adult Human T Cell Leukemia 
 
23 
Sato, K., S. Hida, et al. (2001). "Antiviral response by natural killer cells through TRAIL gene 
induction by IFN-alpha/beta." Eur J Immunol 31 (11): 3138-46 
Sharma, S., N. Grandvaux, et al. (2002). "Regulation of IFN regulatory factor 4 expression in 
human T cell leukemia virus-I-transformed T cells." J Immunol 169 (6): 3120-30 
Sharma, S., Y. Mamane, et al. (2000). "Activation and regulation of interferon regulatory 
factor 4 in HTLV type 1-infected T lymphocytes." AIDS Res Hum Retroviruses 16 
(16): 1613-22 
Sheikh, M. S., T. F. Burns, et al. (1998). "p53-dependent and -independent regulation of the 
death receptor KILLER/DR5 gene expression in response to genotoxic stress and 
tumor necrosis factor alpha." Cancer Res 58 (8): 1593-8 
Sheridan, J. P., S. A. Marsters, et al. (1997). "Control of TRAIL-induced apoptosis by a family 
of signaling and decoy receptors." Science 277 (5327): 818-21. 
Siegal, F. P., N. Kadowaki, et al. (1999). "The nature of the principal type 1 interferon-
producing cells in human blood." Science 284 (5421): 1835-7 
Smyth, M. J., E. Cretney, et al. (2001). "Tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell 
protection from tumor metastasis." J Exp Med 193 (6): 661-70 
Stary, G., I. Klein, et al. (2009). "Plasmacytoid dendritic cells express TRAIL and induce 
CD4+ T-cell apoptosis in HIV-1 viremic patients." Blood 114 (18): 3854-63 
Takenouchi, N., K. S. Jones, et al. (2007). "GLUT1 is not the primary binding receptor but is 
associated with cell-to-cell transmission of human T-cell leukemia virus type 1." J 
Virol 81 (3): 1506-10 
Tecchio, C., V. Huber, et al. (2004). "IFNalpha-stimulated neutrophils and monocytes release 
a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) 
displaying apoptotic activity on leukemic cells." Blood 103 (10): 3837-44 
Tendler, C. L., S. J. Greenberg, et al. (1991). "Cytokine induction in HTLV-I associated 
myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying 
retroviral pathogenesis." J Cell Biochem 46 (4): 302-11 
Tordjman, R., Y. Lepelletier, et al. (2002). "A neuronal receptor, neuropilin-1, is essential for 
the initiation of the primary immune response." Nat Immunol 3 (5): 477-82 
Uematsu, S., S. Sato, et al. (2005). "Interleukin-1 receptor-associated kinase-1 plays an 
essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} 
induction." J ex Med 201 (6): 915-923 
Uozumi, K. "Treatment of adult T-cell leukemia." J Clin Exp Hematop 50 (1): 9-25 
Valledor, A. F., F. E. Borras, et al. (1998). "Transcription factors that regulate 
monocyte/macrophage differentiation." J Leukoc Biol 63 (4): 405-17 
Verdonck, K., E. Gonzalez, et al. (2007). "Human T-lymphotropic virus 1: recent knowledge 
about an ancient infection." Lancet Infect Dis 7 (4): 266-81 
Vidalain, P. O., O. Azocar, et al. (2000). "Measles virus induces functional TRAIL production 
by human dendritic cells." J Virol 74 (1): 556-9 
Vidalain, P. O., O. Azocar, et al. (2001). "Measle virus-infected dendritic cells develop 
immunosuppressive and cytotoxic activities." Immunobiology 204 (5): 629-38 
Walczak, H. and T. L. Haas (2008). "Biochemical analysis of the native TRAIL death-
inducing signaling complex." Methods Mol Biol 414: 221-39 
www.intechopen.com
 T-Cell Leukemia 
 
24
Walczak, H., R. E. Miller, et al. (1999). "Tumoricidal activity of tumor necrosis factor-related 
apoptosis-inducing ligand in vivo." Nat Med 5 (2): 157-63 
Wiley, S. R., K. Schooley, et al. (1995). "Identification and characterization of a new member 
of the TNF family that induces apoptosis." Immunity 3 (6): 673-82 
Wu, G. S., T. F. Burns, et al. (1997). "KILLER/DR5 is a DNA damage-inducible p53-regulated 
death receptor gene." Nat Genet 17 (2): 141-3 
Yamaguchi, K. (1994). "Human T-lymphotropic virus type I in Japan." Lancet 343 (8891): 
213-6 
Yang, G. X., Z. X. Lian, et al. (2005). "Plasmacytoid dendritic cells of different origins have 
distinct characteristics and function: studies of lymphoid progenitors versus 
myeloid progenitors." J Immunol 175 (11): 7281-7 




Edited by Dr Olga Babusikova
ISBN 978-953-307-400-9
Hard cover, 234 pages
Publisher InTech
Published online 26, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The purpose of this book is to provide a comprehensive review of the scientific advances in T-cell
malignancies and to highlight the most relevant findings that will help the reader understand both basic
mechanisms of the disease and future directions that are likely to lead to novel therapies. In order to assure a
thorough approach to these problems, contributors include basic scientists, translational researchers and
clinicians who are experts in this field. Thus, the target audience for this book includes both basic scientists
who will use this book as a review of the advances in our fundamental knowledge of the molecular
mechanisms of T-cell malignancies, as well as clinicians who will use this book as a tool to understand
rationales for the development of novel treatments for these diseases.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Jean-Philippe Herbeuval (2011). Adult Human T Cell Leukemia, T-Cell Leukemia, Dr Olga Babusikova (Ed.),
ISBN: 978-953-307-400-9, InTech, Available from: http://www.intechopen.com/books/t-cell-leukemia/adult-
human-t-cell-leukemia
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
